BACKGROUND
Evidence suggests that gut flora may play an important role in the pathophysiology of the irritable bowel syndrome (IBS). We evaluated rifaximin, a minimally absorbed antibiotic, as treatment for IBS.
METHODS
In two identically designed, phase 3, double-blind, placebo-controlled trials